Bixiye
QP61-22 Free Continuing Education for Mental Health Providers through 12/31/22
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Natiijooyinka Raadinta
Soo bandhiga 1331 - 1340 ee natiijooyinka 4296
Bixiye
QP62-22 Commercial Pharmacy Benefit Exclusion for Propel®, Propel Mini®, Sinuva®
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP63-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Ryplazim® (plasminogen, human-tvmh)
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2022
Bixiye
QP55-22 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2022
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP56-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Cibinqo™ (abrocitinib)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP57-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Pyrukynd® (mitapivat)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP58-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Recorlev® (levoketoconazole)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP59-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Tarpeyo™ (budesonide)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022
Bixiye
QP60-22 MHCP Pharmacy Benefit Exclusion for Camcevi™ (leuprolide)
Taariikhda dhaqangalka Barnaamijka: Jul 13, 2022